Debt-free Balance Sheet And Materially Higher EquityA zero-debt capital structure with materially higher equity meaningfully reduces near-term leverage and refinancing risk. This durable de-risking increases strategic optionality—supporting continued R&D spending, partnership negotiations, or selective financings without immediate solvency pressure.

Improving Cash Burn And Narrower Net Loss TrendA multi-period reduction in cash burn and slightly narrower net losses signals operational progress and more efficient use of R&D resources. If sustained, this improves runway and reduces the frequency/size of external financings, enhancing resilience across the next 2–6 months.

Focused Oncology R&D With Licensing/partnering Revenue ModelA clear, partnership-centric business model suits a pre-commercial biotech: it enables capital-light commercialization via milestones and royalties, leverages partners' regulatory/commercial capabilities, and can accelerate value realization without requiring full internal commercialization scale.

Bears Say

Persistent Operating And Net LossesSustained operating and net losses indicate the company is not yet generating profit from activities and are eroding shareholder value. Over the medium term this limits reinvestment capacity, reduces financial flexibility, and makes long-term viability dependent on successful clinical outcomes or outside funding.

Consistent Negative Operating And Free Cash FlowPersistent negative cash flow forces reliance on external capital to fund R&D and operations; regular financings dilute shareholders and create execution risk. Continued negative flows constrain the ability to invest opportunistically or absorb clinical setbacks without material funding events.

Pre-commercial Status With Effectively Zero RevenueWith negligible product revenue and a pre-commercial pipeline, the company lacks scalable, predictable cash generation. Long-term value creation hinges on uncertain clinical and partnering outcomes, making operational continuity and growth contingent on binary development events.

4575 FAQ

What was CanBas Co., Ltd.’s price range in the past 12 months?

CanBas Co., Ltd. lowest stock price was ¥730.00 and its highest was ¥1558.00 in the past 12 months.

What is CanBas Co., Ltd.’s market cap?

CanBas Co., Ltd.’s market cap is ¥15.87B.

When is CanBas Co., Ltd.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were CanBas Co., Ltd.’s earnings last quarter?

Currently, no data Available

Is CanBas Co., Ltd. overvalued?

According to Wall Street analysts CanBas Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does CanBas Co., Ltd. pay dividends?

CanBas Co., Ltd. does not currently pay dividends.

What is CanBas Co., Ltd.’s EPS estimate?

CanBas Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does CanBas Co., Ltd. have?

CanBas Co., Ltd. has 19,713,655 shares outstanding.

What happened to CanBas Co., Ltd.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of CanBas Co., Ltd.?

Currently, no hedge funds are holding shares in JP:4575

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

CanBas Co., Ltd.

CanBas Co., Ltd., a clinical stage biopharmaceutical company, develops therapeutics for cancer patients. It develops CBP501, a calmodulin-modulating peptide to treat various cancer; and CBS9106, a reversible exportin-1inhibitor that is in Phase I clinical trial for the treatment of solid tumors. The company has a collaboration alliance with Stemline Therapeutics, Inc. CanBas Co., Ltd. was incorporated in 2000 and is based in Numazu, Japan.